Oragenics Stock Set to Reverse Split on Monday, January 22nd (OGEN)

Oragenics Inc (NYSEAMERICAN:OGEN) shares are scheduled to reverse split before the market opens on Monday, January 22nd. The 1-10 reverse split was announced on Monday, January 8th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 19th.

Shares of Oragenics (NYSEAMERICAN:OGEN) traded up $0.44 on Monday, reaching $2.70. 178,113 shares of the company’s stock were exchanged, compared to its average volume of 214,720. Oragenics has a 1 year low of $0.17 and a 1 year high of $8.50. The company has a market capitalization of $111.36, a price-to-earnings ratio of -1.40 and a beta of 1.05.

ILLEGAL ACTIVITY NOTICE: “Oragenics Stock Set to Reverse Split on Monday, January 22nd (OGEN)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/oragenics-stock-set-to-reverse-split-on-monday-january-22nd-ogen.html.

About Oragenics

Oragenics, Inc develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering.

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply